Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones
Imidazo[1,2-α]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.
Colletti, Steven L.,Frie, Jessica L.,Dixon, Elizabeth C.,Singh, Suresh B.,Choi, Bernard K.,Scapin, Giovanna,Fitzgerald, Catherine E.,Kumar, Sanjeev,Nichols, Elizabeth A.,O'Keefe, Stephen J.,O'Neill, Edward A.,Porter, Gene,Samuel, Koppara,Schmatz, Dennis M.,Schwartz, Cheryl D.,Shoop, Wesley L.,Thompson, Chris M.,Thompson, James E.,Wang, Ruixiu,Woods, Andrea,Zaller, Dennis M.,Doherty, James B.
p. 349 - 352
(2007/10/03)
More Articles about upstream products of 500187-60-0